Research view
Switch to patient viewGastric and oesophageal cancer: trials that stopped early
Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.
Suspended
Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital
Reason given in the registry “Medtronic owns Covidien \& closed study 11/18/15. Will reapply through Medtronic.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.
- Ended
- Jul 2024
- Run by
- Tenwek Hospital
- Registry record
- NCT02146508
Withdrawn
Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer
Reason given in the registry “Due to a lack of staff in the department, no inclusion could be realized.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.
- Ended
- Sept 2024
- Run by
- Centre Hospitalier Universitaire de Saint Etienne
- Registry record
- NCT04835987
Withdrawn
SOX-based CRT for Esophageal Cancer.
Reason given in the registry “No eligible patients enrolled. We have to withdraw the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2023.
- Ended
- Dec 2023
- Phase
- Phase 1/2
- Run by
- Zhejiang Provincial People's Hospital
- Registry record
- NCT03991104
Withdrawn
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Reason given in the registry “Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies involving EP0057.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2023.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- Ellipses Pharma
- Registry record
- NCT05411679
Suspended
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Reason given in the registry “Due to a Dose Limiting Toxicity in another sister trial with same technology.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Apr 2023.
- Phase
- Phase 1
- Run by
- Bellicum Pharmaceuticals
- Registry record
- NCT04650451
Withdrawn
Gastrointestinal Anastomosis Using MonoPlus® Suture
Reason given in the registry “The GASTROMO study has been stopped early before enrolling its first patient because the results of our primary endpoint would have been inconsistent. The variability of the leakage rate between all anastomosis included in the study was overly high.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Apr 2023.
- Ended
- Dec 2023
- Run by
- Aesculap AG
- Registry record
- NCT04811833
Withdrawn
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Reason given in the registry “Funding unavailable.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Nov 2022.
- Phase
- Phase 2
- Run by
- Zhonglin Hao
- Registry record
- NCT05245760
Withdrawn
Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)
Reason given in the registry “Research withdrawal before patient registration due to difficulty in continuing research”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Nov 2022.
- Ended
- Jul 2024
- Run by
- Samsung Medical Center
- Registry record
- NCT05431244
Withdrawn
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Reason given in the registry “One of the investigators is leaving the University.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2021.
- Ended
- Dec 2023
- Phase
- Phase 1/2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04105062
Withdrawn
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Reason given in the registry “Replaced it with another clinical trial”
Quoted unchanged from ClinicalTrials.gov; record updated 19 May 2020.
- Ended
- Sept 2024
- Phase
- Phase 2
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT03704077
Withdrawn
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Reason given in the registry “Change in research focus”
Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2012.
- Run by
- Stanford University
- Registry record
- NCT01031056
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.